医药魔方2023-07-26 10:06
7月24日,Syndax Pharmaceuticals和Incyte共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
网页链接{点...查看全文
产业链观察2023-07-26 01:35
#药闻简讯# 7月24日,$Syndax制药(SNDX)$ 和$因塞特医疗(INCY)$ 共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
AGAVE-201研究是一项随机、开放标签的II期临床试验,共纳入241...查看全文
SeekingBiotech2023-07-24 22:03
SNDX and Incyte announced topline data from the pivotal AGAVE-201 trial of axatilimab in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts
$S...查看全文
智通财经APP获悉,当地时间6月13日,美国FDA宣布批准礼来(LLY.US)和因塞特(INCY.US)联合开发的口服JAK抑制剂巴瑞替尼(英文商品名Olumiant)上市,用于治疗严重斑秃成人患者。值得一提的是,这是美国FDA批准用于治疗斑秃的首款系统性疗法... 网页链接
智通财经APP获悉,美国FDA于当地时间7月29日扩大了礼来(LLY.US)与因塞特医疗(INCY.US)的baricitinib药物(商用名Olumiant)的紧急适用授权(EUA)。根据修订后的EUA,治疗确诊新冠的住院患者时,baricitinib不需与吉利德科学(GILD.US)的Vekl... 网页链接
$因塞特(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-19-058098 Size: 9 KB 网页链接
$因塞特(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-19-058092 Size: 9 KB 网页链接
$因塞特(INCY)$ 内部交易: 2019-11-15,EVP, Human Resources,SWAIN PAULA J ,卖出,2500普通股, $86.46
$因塞特(INCY)$ 内部交易: 2019-11-15,EVP, Human Resources,SWAIN PAULA J ,期权,2500普通股, $64.55
$因塞特(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-19-057276 Size: 9 KB 网页链接
$因塞特(INCY)$ 内部交易: 2019-11-13,EVP & General Counsel,Pasquale Maria E ,期权,76普通股, $65.36
$因塞特(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-19-056610 Size: 7 KB 网页链接
$因塞特(INCY)$ 内部交易: 2019-11-08,Director,DIXON WENDY L ,卖出,41218普通股, $83.87
$因塞特(INCY)$ 内部交易: 2019-11-06,Director,DIXON WENDY L ,卖出,10576普通股, $84.16
$因塞特(INCY)$ 内部交易: 2019-11-07,Director,DIXON WENDY L ,卖出,1540普通股, $83.60